Grace Therapeutics (GRCE) Competitors $2.71 +0.10 (+3.83%) As of 05/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock GRCE vs. HLVX, OPTN, ELUT, TCRX, KYTX, CLYM, BDTX, CRDL, ENTX, and VIGLShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include HilleVax (HLVX), OptiNose (OPTN), Elutia (ELUT), TScan Therapeutics (TCRX), Kyverna Therapeutics (KYTX), Climb Bio (CLYM), Black Diamond Therapeutics (BDTX), Cardiol Therapeutics (CRDL), Entera Bio (ENTX), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. HilleVax OptiNose Elutia TScan Therapeutics Kyverna Therapeutics Climb Bio Black Diamond Therapeutics Cardiol Therapeutics Entera Bio Vigil Neuroscience HilleVax (NASDAQ:HLVX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Which has stronger earnings & valuation, HLVX or GRCE? Grace Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHilleVaxN/AN/A-$123.57M-$3.00-0.64Grace TherapeuticsN/AN/A-$12.85M-$1.16-2.34 Do analysts prefer HLVX or GRCE? HilleVax currently has a consensus target price of $3.00, suggesting a potential upside of 55.44%. Grace Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 342.80%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HilleVax 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of HLVX or GRCE? 86.4% of HilleVax shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 71.1% of HilleVax shares are owned by company insiders. Comparatively, 13.5% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, HLVX or GRCE? HilleVax has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Does the MarketBeat Community prefer HLVX or GRCE? HilleVax received 9 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 55.56% of users gave HilleVax an outperform vote. CompanyUnderperformOutperformHilleVaxOutperform Votes1055.56% Underperform Votes844.44% Grace TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Is HLVX or GRCE more profitable? Grace Therapeutics' return on equity of -20.10% beat HilleVax's return on equity.Company Net Margins Return on Equity Return on Assets HilleVaxN/A -67.27% -51.99% Grace Therapeutics N/A -20.10%-17.10% Does the media refer more to HLVX or GRCE? In the previous week, HilleVax had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 3 mentions for HilleVax and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat HilleVax's score of 1.22 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment HilleVax Positive Grace Therapeutics Very Positive SummaryGrace Therapeutics beats HilleVax on 10 of the 15 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.48M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.347.3222.5918.54Price / SalesN/A241.43401.35103.29Price / CashN/A65.8538.1834.62Price / Book0.536.486.774.25Net Income-$12.85M$143.41M$3.22B$248.18M7 Day Performance8.84%2.58%1.39%1.03%1 Month Performance17.32%5.00%2.78%2.70%1 Year PerformanceN/A-3.72%15.85%4.05% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.3855 of 5 stars$2.71+3.8%$12.00+342.8%N/A$27.48MN/A-2.34N/APositive NewsGap DownHLVXHilleVax2.775 of 5 stars$1.86+4.5%$3.00+61.3%-85.8%$93.26MN/A-0.6020Upcoming EarningsNews CoveragePositive NewsOPTNOptiNose3.2582 of 5 stars$9.18+0.1%$9.00-2.0%-31.1%$92.97M$78.23M-2.19190Short Interest ↓News CoveragePositive NewsELUTElutia3.3064 of 5 stars$2.29+0.9%$9.00+293.0%-22.5%$92.47M$24.38M-0.88180Upcoming EarningsShort Interest ↑News CoverageGap UpTCRXTScan Therapeutics3.7624 of 5 stars$1.63+3.8%$9.33+472.6%-82.0%$92.24M$2.82M-1.54100Positive NewsKYTXKyverna Therapeutics1.7936 of 5 stars$2.13+1.4%$18.33+760.7%-86.6%$92.06M$7.03M-0.6196News CoverageGap DownCLYMClimb Bio2.8179 of 5 stars$1.34+4.7%$10.00+646.3%N/A$90.42MN/A-0.639BDTXBlack Diamond Therapeutics3.5262 of 5 stars$1.58+1.3%$14.60+824.1%-71.2%$89.53MN/A-1.1990Upcoming EarningsNews CoveragePositive NewsGap DownCRDLCardiol Therapeutics2.0261 of 5 stars$1.08+9.1%$8.40+677.8%-45.6%$89.22MN/A-2.7720ENTXEntera Bio2.1498 of 5 stars$2.07+5.6%$10.00+383.1%+11.5%$89.03M$181,000.00-7.9620Upcoming EarningsNews CoverageVIGLVigil Neuroscience3.4687 of 5 stars$1.81+0.6%$16.25+797.8%-3.4%$88.91MN/A-0.8840Upcoming Earnings Related Companies and Tools Related Companies HilleVax Alternatives OptiNose Alternatives Elutia Alternatives TScan Therapeutics Alternatives Kyverna Therapeutics Alternatives Climb Bio Alternatives Black Diamond Therapeutics Alternatives Cardiol Therapeutics Alternatives Entera Bio Alternatives Vigil Neuroscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRCE Stock Free GRCE Stock Alerts